Drugs / STX-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07751042 | Jun 2026 → Jul 2030 expected | neoplasm | Strand Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07751042 ↗ |
| Route | Intravenous | “STX-003 administered intravenously” NCT07751042 ↗ |